Biotech Values

[DewDiligence]

DNDN article in Friday’s WSJ:

http://online.wsj.com/article/SB10001424053111903366504576488044215714126.html

Analysts questioned whether the company's explanation told the whole story. They pointed out that a company expecting a short-term problem likely wouldn't take the drastic step of cutting jobs [especially jobs in manufacturing]—often the move of a company adjusting to the new realities of its business model.

"Management's reason is addressable reimbursement issues whereas there are many reasons to believe this is at least in part also a permanent demand issue," Goldman Sachs analyst Sapna Srivastava said, in a note to clients.